Physician
Hematology
Dr. Lance C. Pagliaro, MD
|
|
Give Review
Lance Pagliaro is an expert in the field of Hematology. He studied medicine at Albany Medical College. Lance Pagliaro has written publications. He has 97 publications published with PubMed. The lastest paper is: 'Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.' He is registered with Medicare.
Publications
- Hepatocyte growth factor/cMET pathway activation enhances Cancer hallmarks in adrenocortical carcinoma.
- Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes.
- Testicular chorioCarcinoma: a rare variant that requires a unique treatment approach.
- Clinically nonmetastatic renal Cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
- Prognostic Factors Influencing Survival from Regionally Advanced Squamous Cell Carcinoma of the Penis After Preoperative Chemotherapy.
- Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate Cancer.
- Invasive extramammary Paget's disease of the Bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva.
- Management of Advanced Primary Urethral Carcinomas.
- Implications for human papillomavirus in penile Cancer.
- Adrenocortical Carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center.
- Epidermal Growth Factor Receptor-Targeted Therapy in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.
- Outcomes of patients with metastatic clear-Cell renal Cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
- Current Concepts in Penile Cancer.
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma.
- Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma.
- Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral Carcinomas referred to medical oncologists(☆).
- Malignant Small Round Blue Cell Tumor of the Kidney Without EWSR1 Rearrangement: Report of a Case and Review of the Literature.
- Penoscrotal Extramammary Paget's Disease: The University of Texas M. D. Anderson Cancer Center Contemporary Experience.
- Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate Cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defen...
- Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment.
- Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature (February).
- Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas M. D. Anderson Cancer Center experience.
- Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile Cancer: a phase II study.
- Testicular Cancer: when less is more.
- Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal Cell carcinoma: clinical and biomarker an...
- Association between lymph node density and disease specific survival in patients with penile Cancer.
- Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal Cell carcinoma.
- Choroidal and conjunctival metastases from renal Cell carcinoma.
- Choosing treatment for stage I seminoma: who should get what?
- Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate Cancer previously treated with docetaxel-based the...
- Ischemic optic neuropathy associated with low-dose interferon alfa: report of two cases.
- Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate Cancer.
- Salvage therapy for radiorecurrent prostate Cancer.
- Adaptive therapy for androgen-independent prostate Cancer: a randomized selection trial of four regimens.
- Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate Cancer with bone metastases.
- Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous Cell carcinoma.
- Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose v...
- Phase II study of capecitabine single-agent therapy in patients with metastatic renal Cell carcinoma.
- Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate Cancer.
- Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal Cell carcinoma.
- Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate Cancer previously treated with taxanes.
- Therapy tolerance in selected patients with androgen-independent prostate Cancer following strontium-89 combined with chemotherapy.
- Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem Cell transp...
- Adenoviral p53 gene transfer in human bladder Cancer cell lines: cytotoxicity and synergy with cisplatin.
- Treatment of refractory urothelial Carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).
- A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate Carcinoma and bone metastases.
- Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder Cancer: a phase I study of p53 gene therapy.
- Bone marrow purging studies in Acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
- Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate Carcinoma.
- Treating refractory advanced or metastatic urothelial Carcinoma with interleukin-2: a phase II study.
- Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-Cell carcinoma.
- Early detection of hepatoCellular carcinoma associated with cirrhosis by ultrasound and alfafetoprotein: a prospective study.
- Treatment of hepatoCellular carcinoma: a systematic review of randomized controlled trials.
- Treatment of small hepatoCellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group.
- Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.
- Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease.
- Smoking habits and recurrence in Crohn's disease.
- Primary small noncleaved Cell lymphoma of kidney.
- [Echography in patients with clinically suspected pancreatic Carcinoma. Analysis of a prospective study].
- Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. Liver Study Group ...
- MTHFR C677T mutations in liver cirrhosis with and without portal Vein thrombosis.
- Clinical presentation and ultrasonography in the diagnosis of pancreatic Cancer.
- Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature.
- Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials.
- A randomized clinical trial of propranolol for the prevention of initial bleeding in cirrhosis with portal hypertension.
- A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Mu...
- Preoperative radiotherapy for resectable rectal Cancer: A meta-analysis.
- Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital.
- Survival and prognostic indicators in compensated and decompensated cirrhosis.
- Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis.
- Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months.
- Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection.
- Liver transplantation: the Italian experience.
- Treatment of small hepatoCellular carcinoma with percutaneous ethanol injection: a validated prognostic model.
- Review of metastatic bladder Cancer.
- TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials.
- HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
- Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial.
- Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic f...
- Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. A meta-analysis of 4 randomized clinical trials.
- Prognostic indicators of successful endoscopic sclerotherapy for prevention of rebleeding from oesophageal varices in cirrhosis: a long-term cohort study.
- Ascites, pleural, and pericardial effusions in Acute pancreatitis. A prospective study of incidence, natural history, and prognostic role.
- Long-term course of interferon-treated chronic hepatitis C.
- Retinoblastoma gene in malignancy.
- Dexrazoxane''s protection of jejunal crypt Cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity.
- Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.
- Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.
- Ultrasonographic and radionuclide detection of hepatoCellular carcinoma in cirrhotics with low alpha-fetoprotein levels.
- Polymyositis associated with chronic myelogenous Leukemia.
- A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.
- Adriamycin treatment for hepatoCellular carcinoma. Experience with 109 patients.
- Recombinant human retinoblastoma protein inhibits Cancer cell growth.
- Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in Acute myelogenous leukemia cell lines.
- Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse.
- Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate Cancer.
Schools
Albany Med Coll
Geo Wash University School Med Mc
MD Anderson Cancer Center
Procedures Preformed
- Prostate Cancer Screening Exam (DRE)
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
George Washington University -
Albany Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center -
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1568553311 | |
| NPPES Provider LastName | PAGLIARO | |
| NPPES Provider FirstName | LANCE | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 559.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 56.0 | |
| Percent Opioid Claims | 10.02 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568553311 |
| Last Name Of The Provider | PAGLIARO |
| First Name Of The Provider | LANCE |
| View All |
Similar Doctors
|
Dr. Shirley A. Riggs, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francisco J. Esteva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paolo Anderlini, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mohammad Riaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sumit K. Subudhi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dejka M. Araujo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Navid Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry J. Conter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jun Zhang, MD |
|
|
Dr. Linus Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed K. Azeemuddin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan T. Hennessy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katayoun Rezvani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Parijatham S. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lixin Zhang, MD |